Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer Inc. today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, ...

Donald Trump has signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines ...

Drugmakers Pfizer and Flynn Pharma have been ... so they were no longer subject to price regulations. Pfizer hiked the price of the drug between 780% and 1,600%, and also supplied the drug to ...

Trump signed a similar executive order in the final weeks of his first term, but a court order later blocked the rule from ...

The US-UK trade deal gives the Irish government and EU negotiators some indication of the potential negotiating tactics to ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. | A federal jury in Delaware has ...

Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron ...

Instead, said Kaitin, drugs hit the US market first because the sponsors choose to submit them there first. The advantage of the US is almost wholly down to its lack of price controls, says Kaitin.